John Garner

PLGA-PEG-COOH from PolySciTech used in development of nanoparticle therapy for breast cancer.

Blog Post created by John Garner on Jul 1, 2019

2019 breast cancer polyscitech PLGA-PEG-COOH

Targeting cancer at higher rates than normal tissue is the goal of drug delivery in the cancer sector so as to maximize efficacy with minimal side-effects. Recently, researchers from China Pharmaceutical University Used PLGA-PEG-COOH (AI034) from PolySciTech ( as part of development of aptamer-targeted nanoparticles for cancer delivery. This research holds promise for the development of advanced breast cancer treatment options. Read more: Duan, Tao, Zhuobin Xu, Fumou Sun, Yang Wang, Juan Zhang, Chen Luo, and Min Wang. "HPA aptamer functionalized paclitaxel-loaded PLGA nanoparticles for enhanced anticancer therapy through targeted effects and microenvironment modulation." Biomedicine & Pharmacotherapy 117 (2019): 109121.

“Highlights: Confirming HPA as recognized molecular targets for TNBC therapy. A HPA aptamer-guided anticancer drug delivery system was developed with MDA-MB-231 as a model in vitro and vivo. The system exhibited enhanced anti-invasive and anti-angiogenesis activity through HPA-related signaling pathways. Numerous cancers overexpress HPA and are sensitive to PTX, that make the system as a broad-spectrum anti-cancer agent. Abstract: Breast cancer is a fairly common cancer with high mortality in women worldwide. Targeted nano-drug delivery system for breast cancer treatment has achieved encouraging results, because of increased drug concentration at the tumor site, thereby improving biocompatibility and blood half-life while reducing chemoresistance. However, the absence of available target on cancer cells is one of the major obstacles for triple-negative breast cancer (TNBC). Increasing studies have shown that heparanase (HPA) is highly expressed in many cancers, including TNBC. Thus paclitaxel(PTX) -encapsulated PEGylated PLGA nanoparticles were developed and further surface-functionalized with the HPA aptamers (Apt(S1.5)-PTX-NP). Moreover, targeting and cytotoxicity of Apt(S1.5)-PTX-NP to TNBC cells were evaluated with MDA-MB-231 as a model. These nanoparticles bonded to the HPA overexpressed on the surface of TNBC cells and were taken up by these cells, resulting in remarkably enhanced cellular toxicity compared with non-targeted PTX-NP that lack the HPA aptamer (P < 0.01). Furthermore, Apt(S1.5)-PTX-NP significantly exhibited enhanced anti-invasive and superior anti-angiogenesis activity compared with those of other experiment groups at low administration dosage. The Apt(S1.5)-PTX-NP demonstrated the most dramatic efficacy with the final mean tumor sizes of 157.30 ± 41.09 mm3 (mean ± SD; n = 10) in vivo treatment. Thus, the present study indicated that HPA is a promising target for drug delivery to TNBC cells, and nanoparticle-HPA-aptamer bioconjugates can provide new insights for TNBC treatment.”

Biotech, Pharma, Cancer, Research (BPCR) is a free, 1-day scientific networking conference hosted by Akina, Inc. on Aug 28, 2019. See more and register to attend at